Purchase this article with an account.
N. Feucht, M. Huebner, C. P. Lohmann, M. Maier; Clinical Experience With Pegaptanib in the Treatment of Neovascular AMD. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1827. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Intravitreal anti-VEGF therapy with Pegaptanib was effective in neovascular AMD in the VISION-study. We report our compassionate use and clinical experience with Macugen before and after approval in the European Union (EU).
50 eyes of 50 Patients with occult CNV or minimally classic CNV due to neovascular AMD not eligible for PDT were treated with intravitreal injection of Pegaptanib. Prior to admission of Macugen in the EU we started treating the first patients September 2005. Before and every 3 month after treatment visual acuity, intraocular pressure measurement, angiography and OCT examination were performed. Visual acuity measurements and an eye examination was done on the second day and after 4 weeks.
Intravitreal Pegaptanib was well tolerated and we had no complications. Of the 25 patients with more than 1 injection in 22 patients (88%) visual acuity was stabilized or improved and in fluorescein angiography and OCT leakage and retinal thickness was stabilized.
Intravitreal therapy with Pegaptanib was safe. After intravitreal application of Pegaptanib visual acuity was stabilized or improved and retinal thickness and leakage were nearly unchanged. Since Pegaptanib intravitreally is now approved in the EU it is a therapeutic option for treatment of exsudative AMD.
This PDF is available to Subscribers Only